Modification of membrane fluidity and depolarization by some anthracyclines in different cell lines

Anticancer Research

Volumn 18, Issue 6 A, 1998, Pages 4027-4034

  Pacilio, C ^b   Florid, S ^a   Pagnini, U ^a   Crispino, A ^a   Claudio, P P ^b   Pagilio, G ^c   Pagnini, G ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c CARDARELLI HOSPITAL   (Italy)

Author keywords

Anthracyclines; Depolarization; Membrane fluidity

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; IDARUBICIN; MEDROXYPROGESTERONE ACETATE; VERAPAMIL;

ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DEPOLARIZATION; DRUG EFFECT; HEART MUSCLE CELL; HUMAN; HUMAN CELL; LIPID BILAYER; LYMPHOCYTE; MEMBRANE FLUIDITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTHRACYCLINES; BREAST NEOPLASMS; CELL LINE; CELL MEMBRANE; CELLS, CULTURED; DOXORUBICIN; FEMALE; HUMANS; IDARUBICIN; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKOCYTES; LIPID BILAYERS; LYMPHOCYTES; MEDROXYPROGESTERONE 17-ACETATE; MEMBRANE FLUIDITY; MEMBRANE POTENTIALS; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; TUMOR CELLS, CULTURED; VERAPAMIL;

EID: 0032423959     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Peterson RH, Meyers MB, Spengle BA and Biedler J: Alteration of plasma membrane glycopeptides and gangliosydes of Chinese hamster cells accompanying development of resistance to daunorubicin and vincristine. Cancer Res 43: 222-228, 1983.
2. Rintoul DA and Cente MS: Involvement of plasma membrane lipid structural order in adriamycin resistance in Chinese hamster lung cells. Cancer Res 44: 4978-4980, 1984.
3. Wheeler C, Rader L and Kessel D: Membrane alterations associated with progressive adriamycin resistance. Biochem Pharmacol 31: 2691-2693, 1982.
4. Callaghan R, Stafford A and Kessel D: Increased accumulation of drugs in a multidrug resistant cell line by alteration of membrane biophysical properties. Biochem Biophys Acta 1175: 277-282, 1993.
5. Drori S, Eytan GD and Assaraf YG: Potentiation of anticancer - drug cytotoxicity by multidrug - resistance chemosensitizers involves alterations in membrane fluidity leading to increase membrane permeability. Eur J Biochem 228: 1020-1029, 1995.
6. Marutaka M, Iwagaki H, Sugury T, Tanaka N and Orita K: Alterations of membrane fluidity in K562 cells exposed to the anticancer drug adriamycin. Res. Commun Mol Pathol Pharmacol 85: 163-170, 1994, 1994.
7. Ramu A, Glanbiger D, Magrath IT and Joshi A: Plasma membrane lipid structural order in doxorubicin-sensitive and resistant P 388 cells. Cancer Res 43: 5533-5537, 1983.
8. Siegfried JA, Kennedy KA, Sartorelli AC and Tritton TR: The role of membranes in the mechanism of action of the antineoplastic agent of adriamycin. Spin-labelled studies with chronically hypoxic and drug-resistant tumor cells. J Biol Chem 258: 339-343, 1983.
9. Mann SK, Andrews PA and Howell SB: Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diammine dichloroplatinum (II accumulation in sensitive and resistant human ovarian carcinoma cells. Anticancer Res 8: 1211-1215, 1988.
10. Plumb JA, Luo W and Kerr DJ: Effects of polyunsaturated fatty acids on the drug sensitivity of human tumor cell lines resistant to either cisplatin or doxorubicin. Br J Cancer 67: 728-733, 1993.
11. Escriba PV, Ferrier-Montiel AV, Ferragut, JA and Gonzales- Ros JM: Role of membrane lipids in the interaction of daunomycin with plasma membrane from tumor cells: implications in drug resistance phenomena. Biochemistry 29: 7275-7278, 1990
12. De Wolf FA, Maliepaard M, Van Dorsten F, Berghuis I, Nicolay K and de Kruijff B: Comparable interaction of doxorubicin with various acidic phospholipids results in changes of lipid order and dynamics. Biochim Biophys Acta 1096: 67-80, 1990.
13. De Wolf FA, Staffhorst RW, Smits HP, Onwezen MF and De Kruijff B: Role of anionic phospholipids in the interaction of doxorubicin and plasma membrane vescicles: drug binding and structural consequences in bacterial systems. Biochemistry 32: 6688-6695, 1993.
14. Cavalli F, Goldhrisch A, Jungi F, Martz G, Mermillod B and Alberto, P: Randomized trial of low versus high dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer. J Clin Oncol 2: 414-419, 1984.
15. Bojar H, Stuschke M, and Staib W: Effects of high dose medroxyprogesterone acetate on plasma membrane lipid mobility. Prog Cancer Res Ther 31: 115-119, 1984.
16. Hupperets PS, Wils J, Volovics L, Schuten L, Fickers M, Bron H, Schouten H, Jager J, Smeets J, and De Jong J: Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluoruracile (CAP with or without medroxyprogesterone acetate for node positive breast cancer patients. Ann Oncol 4: 295-301, 1993.
17. Anderstrom C: Experiences with doxo/epirubicin and medroxyprogestrone acetate (MPA in prostatic cancer). Cancer Chemother Pharmacol 35, Suppl. S97-S100, 1994.
18. Lecureur V, Fardel O, Guillouzo A: The antiprogestatin drug RU-486 potentiates doxorubicin cytotoxicity in multidrug resistant cells through inhibition of P-glycoprotein function. FEBS-Lett. 355: 187-191, 1994.
19. Ohba S, Hiramatsu M, Edamatsu R, Mori I and Mori A: Metal ions affect neuronal membrane fluidity of rat cerebral cortex. Neurochem Res 19: 237-241, 1994.